| Quarterly Financials | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 622 | 572 | 573 | 547 | 579 | 503 | 526 | 529 | 539 |
| Expenses | 368 | 393 | 377 | 370 | 400 | 367 | 404 | 397 | 364 |
| EBITDA | 254 | 179 | 195 | 177 | 179 | 137 | 122 | 132 | 175 |
| Operating Profit % | 29 % | 24 % | 23 % | 21 % | 22 % | 21 % | 23 % | 23 % | 32 % |
| Depreciation | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 10 |
| Interest | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 244 | 169 | 186 | 167 | 169 | 127 | 113 | 122 | 165 |
| Tax | 54 | 46 | 34 | 30 | 33 | 24 | 30 | 31 | 46 |
| Net Profit | 190 | 123 | 152 | 138 | 137 | 103 | 82 | 91 | 120 |
| EPS in ₹ | 82.78 | 53.37 | 65.95 | 59.79 | 59.31 | 44.81 | 35.69 | 39.64 | 51.89 |
Sanofi
Sanofi
4,748.40
+53.90
(1.15%)
There are 4 new updates from the company1 day ago
View
Key Fundamentals
Market Cap
10,811.70 Cr
EPS
179.46
PE Ratio
27.35
Dividend Yield
2.48 %
Industry
Healthcare 52 Week High
6,899.00
52 Week Low
4,623.50
PB Ratio
12.59
Debt to Equity
0.02
Sector
Pharmaceuticals Analyst Rating and Forecast
- By Refinitiv from2 analysts
Actual
Company News
View All News
Sanofi India Appoints Deepak Arora as Managing Director, Rachid Ayari Steps Down from Interim Role
1 day ago
1 day agoSanofi India Limited's Board of Directors approved the appointment of Deepak Arora as Additional Director and Managing Director for a three-year term starting October 27, 2025, subject to shareholder and Central Government approval. Arora brings over 30 years of pharmaceutical and healthcare experience across North America, Europe, Middle East and Africa in commercial, sales, marketing and general management roles. Simultaneously, Rachid Ayari stepped down from his position as Interim Managing Director effective October 26, 2025, but continues serving as Whole-time Director and Chief Financial Officer. Ayari had been appointed as Interim Managing Director for six months from July 21, 2025, or until a permanent Managing Director was appointed. The Board authorized Arora to determine materiality of events and make stock exchange disclosures alongside other Key Managerial Personnel.
Sanofi India Limited announced key management changes in its Company Secretary position. Arjun Thakkar resigned from his role as Company Secretary and Compliance Officer, effective September 30, 2025, to pursue a career opportunity in the Ethics & Business Integrity department within the Sanofi Group. The Board of Directors appointed Haresh Vala as the new Company Secretary and Compliance Officer, effective October 1, 2025. Vala is an Associate Member of the Institute of Company Secretaries of India with over two decades of experience in corporate secretarial and compliance functions. He holds degrees in Law and Commerce from the University of Mumbai and brings expertise in corporate governance, regulatory compliance, investor relations, SEBI regulations, and Companies Act compliances. The appointment was approved by the Board upon recommendation from the Nomination and Remuneration Committee during their meeting on September 25, 2025.
Sanofi India Seeks Shareholder Approval for Interim Managing Director and New Whole-time Director AppointmentsAug 12, 2025
Sanofi India Limited has dispatched a postal ballot notice seeking shareholder approval for two key appointments. The company proposes to appoint Rachid Ayari as Interim Managing Director for six months from July 21, 2025 to January 20, 2026, or until a permanent Managing Director is appointed. Ayari currently serves as Whole-time Director and Chief Financial Officer, a position he will retain alongside the interim role. The company also seeks approval for Mahadev Gawade's appointment as Director and Whole-time Director for three years from August 11, 2025 to August 10, 2028. Gawade brings over 20 years of experience in logistics and manufacturing in the pharmaceutical industry. The e-voting period runs from August 13 to September 11, 2025, with results to be declared by September 13, 2025. These appointments follow the departure of Rodolfo Hrosz as Managing Director on April 30, 2025.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,687.00 | #1 4,06,351.40 | 39.10 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 60.73 | |
6,438.50 | 1,72,289.10 | 74.71 | 9,712.00 | 18.67 | 2,191 | 26.74 | 57.08 | |
1,568.10 | 1,27,948.20 | 23.76 | 28,409.50 | 7.12 | 5,291 | 9.88 | 50.34 | |
3,576.50 | 1,21,718.50 | 60.78 | 11,539.40 | 6.99 | 1,911 | 19.91 | 50.97 | |
1,289.40 | 1,07,189.40 | #1 18.69 | 33,741.20 | 16.73 | 5,725 | -0.38 | 57.78 | |
1,001.25 | 1,02,017.00 | 21.65 | 23,511.00 | 18.55 | 4,615 | 2.60 | 50.49 | |
2,406.50 | 99,751.30 | 52.11 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 35.88 | |
1,918.70 | 87,829.30 | 23.59 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 42.45 | |
5,432.00 | 65,467.80 | 28.04 | 13,458.30 | 3.70 | 2,216 | 21.39 | 44.72 | |
1,099.40 | 63,580.40 | 18.93 | 32,345.60 | 9.43 | 3,484 | -10.24 | 50.73 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
-1.34 %
Net Income Growth
-13.96 %
Cash Flow Change
100.30 %
ROE
1.50 %
ROCE
-2.71 %
EBITDA Margin (Avg.)
-
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2023 | 2024 |
| Total Assets | 1,715 | 1,612 |
| Fixed Assets | 315 | 313 |
| Current Assets | 1,248 | 1,127 |
| Capital Work in Progress | 16 | 18 |
| Investments | 0 | 0 |
| Other Assets | 1,384 | 1,281 |
| Total Liabilities | 1,715 | 1,612 |
| Current Liabilities | 651 | 719 |
| Non Current Liabilities | 48 | 32 |
| Total Equity | 1,015 | 861 |
| Reserve & Surplus | 992 | 838 |
| Share Capital | 23 | 23 |
Cash Flow
| Cash Flow | 2023 | 2024 |
| Net Cash Flow | -610 | -111 |
| Investing Activities | 38 | -180 |
| Operating Activities | 230 | 462 |
| Financing Activities | -878 | -392 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 6.80 % | 0.00 % | 6.11 % | 5.81 % | 5.78 % | 5.63 % | 5.57 % | 5.61 % | 5.57 % |
| DIIs | 17.16 % | 17.39 % | 17.65 % | 19.03 % | 18.65 % | 18.60 % | 18.27 % | 19.21 % | 19.47 % | 19.66 % | 21.69 % | 22.47 % | 23.08 % | 22.79 % | 22.82 % | 22.93 % | 23.02 % | 23.06 % | 22.29 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 6.97 % | 7.09 % | 7.21 % | 7.01 % | 7.65 % | 7.92 % | 8.81 % | 9.13 % | 9.29 % | 8.89 % | 8.60 % | 8.09 % | 7.97 % | 8.31 % | 8.21 % | 8.33 % | 8.38 % | 8.33 % | 9.08 % |
| Others | 15.48 % | 15.12 % | 14.74 % | 13.56 % | 13.30 % | 13.09 % | 12.53 % | 11.26 % | 10.85 % | 11.05 % | 2.51 % | 9.04 % | 2.44 % | 2.69 % | 2.79 % | 2.70 % | 2.63 % | 2.61 % | 2.67 % |
| No of Share Holders | 0 | 48,465 | 53,567 | 51,646 | 50,916 | 59,276 | 64,542 | 73,734 | 76,694 | 71,513 | 68,598 | 62,870 | 61,849 | 67,662 | 66,211 | 66,401 | 68,196 | 66,790 | 71,395 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 71 | 84 | 349 | 365 | 490 | 570 | 167 | 117 | 0.00 |
| Dividend Yield (%) | 0.00 | 1.37 | 1.44 | 5.58 | 4.63 | 6.53 | 10.15 | 2.06 | 2.04 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 29 Oct 2025 |  Quarterly Result Announcement | NA | 29 Oct 2025 | 4,772.95 | 4,704.45 |
| 21 Apr 2021 |  Dividend | ₹ 125.00 /share | 19 Apr 2021 | 7,919.85 | 7,682.05 |
| 21 Apr 2021 | Dividend | ₹ 240.00 /share | 19 Apr 2021 | 7,919.85 | 7,682.05 |
| 16 Apr 2022 | Dividend | ₹ 181.00 /share | 12 Apr 2022 | 7,136.45 | 7,300.40 |
| 16 Apr 2022 | Dividend | ₹ 309.00 /share | 12 Apr 2022 | 7,136.45 | 7,300.40 |
| 26 Apr 2022 |  Annual General Meeting | NA | 26 Apr 2022 | 7,136.45 | 6,979.40 |
| 08 Aug 2022 | Dividend | ₹ 193.00 /share | 05 Aug 2022 | 6,749.00 | 6,542.60 |
| 29 Apr 2023 | Dividend | ₹ 194.00 /share | 28 Apr 2023 | 5,399.30 | 5,572.25 |
| 29 Apr 2023 | Dividend | ₹ 183.00 /share | 28 Apr 2023 | 5,399.30 | 5,572.25 |
| 11 May 2023 | Annual General Meeting | NA | 11 May 2023 | 5,399.30 | 5,700.45 |
| 18 Dec 2023 |  Extraordinary General Meeting | NA | 18 Dec 2023 | 7,804.20 | 8,054.90 |
| 07 Mar 2024 | Dividend | ₹ 50.00 /share | 07 Mar 2024 | 9,208.85 | 8,529.75 |
| 03 May 2024 | Dividend | ₹ 117.00 /share | 03 May 2024 | 9,208.85 | 8,679.45 |
| 14 May 2024 | Annual General Meeting | NA | 14 May 2024 | 9,208.85 | 7,995.05 |
| 07 Nov 2024 | Quarterly Result Announcement | NA | 07 Nov 2024 | 7,024.25 | 6,583.05 |
| 27 Feb 2025 | Quarterly Result Announcement | NA | 27 Feb 2025 | 5,358.40 | 5,059.65 |
| 25 Apr 2025 | Dividend | ₹ 117.00 /share | 25 Apr 2025 | 5,059.65 | 6,570.50 |
| 14 May 2025 | Quarterly Result Announcement | NA | 14 May 2025 | 5,754.70 | 5,928.60 |
| 15 May 2025 | Annual General Meeting | NA | 15 May 2025 | 5,568.15 | 6,042.35 |
| 31 Jul 2025 | Quarterly Result Announcement | NA | 31 Jul 2025 | 5,955.65 | 5,881.95 |
Announcements
Announcement under Regulation 30 (LODR)-Press Release / Media Release1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Cessation1 day ago
1 day agoBoard Meeting Outcome for Outcome Of The Board Meeting Of The Company Held On 27Th October 20251 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Change in Directorate1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
5 days agoBoard Meeting Intimation for Consideration And Approval Of Unaudited Financial Statements For The Quarter And Nine-Months Ended 30Th September 2025 And Declaration Of Interim Dividend For The Year 2025 If Any.5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication10 days ago
10 days agoDisclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Oct 16, 2025
Oct 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 13, 2025
Oct 13, 2025Closure of Trading WindowSep 26, 2025
Sep 26, 2025Appointment of Company Secretary and Compliance OfficerSep 25, 2025
Sep 25, 2025Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerSep 25, 2025
Sep 25, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportSep 11, 2025
Sep 11, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 23, 2025
Aug 23, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 13, 2025
Aug 13, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 02, 2025
Aug 02, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-RetirementJul 31, 2025
Jul 31, 2025Financial Results For The Quarter And Half-Year Ended 30Th June 2025Jul 31, 2025
Jul 31, 2025Board Meeting Outcome for Financial Results For The Quarter And Half-Year Ended 30Th June 2025Jul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 29, 2025
Jul 29, 2025Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Statements For The Quarter And Half-Year Ended 30Th June 2025Jul 18, 2025
Jul 18, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 16, 2025
Jul 16, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 16, 2025
Jul 16, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 16, 2025
Jul 16, 2025Board Meeting Outcome for Outcome Of Board Meeting Of The Company Held On 16Th July 2025Jul 16, 2025
Jul 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 11, 2025
Jul 11, 2025Closure of Trading WindowJun 25, 2025
Jun 25, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 30, 2025
May 30, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.May 24, 2025
May 24, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 24, 2025
May 24, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 22, 2025
May 22, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportMay 15, 2025
May 15, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 14, 2025
May 14, 2025Financials Results For The Quarter Ended 31St March 2025May 14, 2025
May 14, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On Wednesday 14Th May 2025May 14, 2025
May 14, 2025Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Statements For The Quarter Ended 31St March 2025May 09, 2025
May 09, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 06, 2025
May 06, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 25, 2025
Apr 25, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 24, 2025
Apr 24, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 23, 2025
Apr 23, 2025Business Responsibility and Sustainability Reporting (BRSR)Apr 22, 2025
Apr 22, 2025Notice Of The Sixty Ninth Annual General MeetingApr 22, 2025
Apr 22, 2025Reg. 34 (1) Annual Report.Apr 22, 2025
Apr 22, 2025Mutual Fund Holdings
Aditya Birla Sun Life Small Cap Fund Direct-Growth 
SBI Mid Cap Direct Plan-Growth 
Baroda BNP Paribas Midcap Fund Direct-Growth 
Motilal Oswal Nifty Microcap 250 Index Fund Direct - Growth 
Bandhan BSE Healthcare Index Fund Direct-Growth 
HDFC BSE 500 Index Fund Direct - Growth 
Groww Nifty Total Market Index Fund Direct - Growth 
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth 
Axis Nifty 500 Index Fund Direct-Growth 
Baroda BNP Paribas Health and Wellness Fund Direct-Growth 
Angel One Nifty Total Market Index Fund Direct - Growth 
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth Technical Indicators
RSI(14)
Neutral 36.30
ATR(14)
Less Volatile 80.64
STOCH(9,6)
Neutral 49.77
STOCH RSI(14)
Neutral 64.97
MACD(12,26)
Bullish 17.89
ADX(14)
Strong Trend 43.19
UO(9)
Bearish 41.22
ROC(12)
Downtrend And Accelerating -0.83
WillR(14)
Neutral -61.12
About Sanofi
Sanofi India Limited is a pharmaceutical company primarily engaged in manufacturing and trading drugs and pharmaceuticals. It operates manufacturing facilities in Goa and Ankleshwar, Gujarat, and sells products through independent distributors mainly in India. The company focuses on five therapeutic areas: diabetes, epilepsy, cardiology, allergy, and pain care. Key products include Lantus (insulin), Combiflam (pain relief), Amaryl (anti-diabetic), Allegra (allergy), Cardace (cardiovascular), and Toujeo (long-acting insulin). Sanofi India is majority-owned by Sanofi and its subsidiary Hoechst GmbH, holding 60.37% of its paid-up share capital. The company has undergone several name changes and acquisitions, including the purchase of Universal Medicare's nutraceutical business in 2011. In 2021, Sanofi India sold its Nutraceuticals business to Universal Nutriscience Private Limited, and in 2022-23, its Consumer Healthcare Business was demerged into a wholly-owned subsidiary.
Chairperson NameAditya Narayan
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
